CEL-SCI (CVM) announced that it intends to offer to sell shares of its common stock in a best efforts public offering. The company intends to use the net proceeds from this offering to fund the continued development of Multikine, for general corporate purposes, and working capital. ThinkEquity is acting as sole placement agent for the offering.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CVM:
- CEL-SCI provides rationale for use of Multikine in head, neck cancer study
- CEL-SCI, FDA agree on patient selection approach for Multikine study
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
